Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US Biopharma IPOs: Market's Rally Passes Them By

This article was originally published in Start Up

Executive Summary

Continuing the trend from 2010, biopharma initial public offerings in 2011 are running into stubborn resistance from public investors, a frustrating development as markets otherwise soar to pre-recession levels. More often than not, drug companies are squeezing through the IPO window, which reopened in late 2009, by selling more shares at lower prices. The discounts mean companies raise less cash, and they strain beleaguered venture investors who must hold shares longer to reach an attractive exit price.
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092081

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel